Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma

Fig. 4

KIAA1522 regulates gene expression signatures associated with TNF-NFκB pathway and cisplatin resistance. a-e RNA-sequencing experiments were performed to detect the expression profiling of control and 889 cells depleting of KIAA1522. Each group includes three replicates. a volcano plot shows the different expressed genes of KIAA1522 depleted 889 cells compared to the control cells. The genes with both |log2FC| > 2 and p-value< 0.05 were considered as significantly differentiated genes. b Enrichment analysis of KIAA1522 positively regulated genes in HALLMARK gene signatures, the significantly enriched signatures were ranked by q-values, the bar plot shows the top 20 signatures. c Gene sets enrichment analysis (GSEA) of genes by ranked by log2FC (sgkiaa1522/ sgcontrol) values using a set of TNF-NFκB pathway related signatures. d-e The GSVA score of the genesets related to the TNF-NFκB pathway (d) and experiments derived cisplatin-resistant gene signatures (e) were determined by GSVA algorithm. The heatmaps show the distribution of GSVA values between the indicated group of cells. f The patients in TCGA-LUAD cohort were classified by both KIAA1522 expression and NFκB activity into four groups and subjected to Kaplan–Meier overall survival analysis. The activity of NFκB signaling was determined by the GSVA score of the geneset JAIN_NFKB_SIGNALING. g The genes were ranked by the Pearson correlation coefficient with KIAA1522 expression in TCGA-LUAD datasets. Then, the GSEA assays were performed using a set of NFκB activity positively associated signatures to evaluate the correlation of KIAA1522 expression level with NFκB signaling activity

Back to article page